Evidence map›Paper›PMID 37798907›Full record

ArticleESC heart failure2023

Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction.

Xiaoyan Lin, Weiqiang Liu, Yong Chu, Hailin Zhang, Lishan Zeng, Yifei Lin, Kai Kang, Feng Peng, Jinxiu Lin, Chunkai Huang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Synergistic combinations ofFrontiers in pharmacology · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Xiaoyan LinDepartment of Echocardiology, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Weiqiang LiuCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yong ChuCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Hailin ZhangCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Lishan ZengCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yifei LinCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Kai KangCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Feng PengCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jinxiu LinCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Chunkai HuangCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Dajun ChaiCardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.ORCID 0000-0001-9477-9956
Fujian Medical University · CN

Funding

Joint Funds for the Innovation of Science and Technology of Fujian Province 2018Y9088
6 · The paper itself

Abstract

aimsLeft ventricular remodelling subsequent to myocardial infarction (MI) constitutes a pivotal underlying cause of heart failure. Intervention with the nontoxic endogenous aryl hydrocarbon receptor (AHR) agonist 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) in the acute phase of MI has been shown to ameliorate cardiac function, but its role in the chronic phase remains obscured. This study explores the beneficial role of ITE in delaying the progression of heart failure in the chronic phase of MI. METHODS AND

resultsMI rats established by ligating the left anterior descending coronary artery were treated with the indicated concentration of the AHR agonist ITE or vehicle alone. Echocardiography was performed to determine cardiac structure and function; myocardial morphology and fibrosis were observed by haematoxylin and eosin and Masson's trichrome staining; serum biochemical indices, BNP, and inflammatory cytokine levels were detected by enzyme-linked immunosorbent assay; F4/80

conclusionsThe AHR agonist ITE alleviates cardiomyocyte apoptosis through the Akt/p70S6K signalling pathway, thereby rescuing left ventricular adverse remodelling and cardiac dysfunction after MI.

Indexed as

Heart FailureMyocardial InfarctionAnimalsbcl-2-Associated X ProteinCaspase 3Proto-Oncogene Proteins c-aktRatsReceptors, Aryl HydrocarbonRibosomal Protein S6 Kinases, 70-kDaVentricular Remodelingbcl-2-Associated X ProteinCaspase 3Proto-Oncogene Proteins c-aktReceptors, Aryl HydrocarbonRibosomal Protein S6 Kinases, 70-kDaAHR agonistAkt/p70S6KApoptosisMyocardial infarctionVentricular remodelling

Identifiers

PMID37798907
PMCPMC10682871
OpenAlexW4387392062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.